What is the recommended treatment for aplastic anemia?

Treatment of Aplastic Anemia

For patients under 50 years with severe aplastic anemia (SAA) and an HLA-matched sibling donor, allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be the first-line therapy; for those without a matched sibling donor, immunosuppressive therapy (IST) combining anti-thymocyte globulin (ATG), cyclosporine A, and eltrombopag is the standard treatment. 1

Treatment Algorithm by Patient Age and Disease Severity

Patients < 50 Years Old with Severe/Very Severe AA

First-Line Options:

• HLA-matched sibling donor available: Proceed directly to allo-HSCT 2, 1

  • This offers potential cure with complete hematopoietic recovery
  • Bone marrow is the preferred graft source over peripheral blood 3
  • Use rabbit ATG over horse ATG in conditioning regimens 3
  • Fludarabine-containing regimens are preferred for high-risk patients 3

• No matched sibling donor:

  • Pediatric patients with ≥9/10 loci-matched unrelated donor: Consider allo-HSCT as first-line 2
  • Young patients without matched donor: Haploidentical donor (HID) HSCT is now recommended as first-line option 2
  • Alternative: Triple combination IST with equine or rabbit ATG + cyclosporine A + eltrombopag 1, 4

Critical Decision Point: SAA vs vSAA in Younger Patients

Recent high-quality evidence from 2024 shows important nuances 5:

• For SAA (not very severe): IST + eltrombopag achieves better 3-year overall survival (92.4% vs 82.8%, p=0.017) in patients <40 years
• For vSAA: Haploidentical HSCT achieves better failure-free survival (81.6% vs 69.4%, p=0.002) and faster hematopoietic recovery
• Haplo-HSCT patients achieve 86.3% normal blood counts at 6 months vs only 24.1% with IST + eltrombopag

Patients ≥ 40-50 Years Old

The historical 40-year age cutoff is no longer endorsed 3, 1:

• Age 40-60 with ECOG ≤2:

  • Matched sibling or matched unrelated donor HSCT remains an option 2
  • IST + eltrombopag is equally valid, with no significant OS difference (88.6% vs 82.4%, p=0.517) 5
  • However, HSCT provides better failure-free survival (82.4% vs 58.7%, p=0.043) 5

• Fit older patients: May benefit from HSCT if appropriate donor available 3

Non-Severe AA (Moderate Disease)

• Cyclosporine A monotherapy is recommended for transfusion-independent patients 4
• Transfusion-dependent non-SAA: Follow same guidelines as SAA 2

Immunosuppressive Therapy Details

Standard Triple Combination 1, 4:

1. Anti-thymocyte globulin (ATG):

   • Equine ATG (ATGAM®) now approved and available 4
   • Rabbit ATG is alternative option

2. Cyclosporine A: Continued long-term

3. Eltrombopag (TPO-RA):

   • The addition of eltrombopag to IST is now strongly recommended 1
   • Romiplostim is an alternative TPO-RA option 4
   • Significantly improves response rates

Second-Line Treatment for IST Failure or Relapse

All patients who fail IST or relapse 2, 1:

• Age <50: Haploidentical, matched unrelated donor, or cord blood transplant
• Age 50-60 with ECOG ≤2: Matched sibling or matched unrelated donor transplant
• Alternative: Repeat IST with different ATG preparation or add/optimize TPO-RA

Modern HSCT Advances Changing Practice

Post-transplant cyclophosphamide (PTCy) has revolutionized haploidentical transplantation 6, 3:

• Dramatically reduced graft-versus-host disease risk
• Expanded donor pool significantly
• Made alternative donor HSCT safer and more effective
• PTCy-based GVHD prophylaxis is now recommended alongside calcineurin inhibitor + methotrexate 3

Reduced-toxicity conditioning regimens have improved outcomes 6:

• Disease-free survival after HSCT may now be superior to IST
• Overall survival has improved significantly over recent decades
• Morbidity and mortality after HSCT substantially reduced

Essential Supportive Care

Antimicrobial prophylaxis 1:

• Antibiotic prophylaxis recommended for neutropenic patients
• Antifungal prophylaxis recommended for high-risk neutropenic patients

Additional supportive measures 7:

• Red blood cell and platelet transfusions as needed
• G-CSF for severe neutropenia with infection
• Iron chelation therapy for transfusion-dependent patients with iron overload

Common Pitfalls to Avoid

1. Don't delay HSCT evaluation: Even without matched sibling, haploidentical donors should be considered upfront in appropriate candidates 2, 6

2. Don't use the 40-year cutoff rigidly: Fit older patients may benefit from HSCT 3, 1

3. Don't omit eltrombopag from IST regimens: This significantly improves outcomes 1

4. Don't use peripheral blood stem cells when bone marrow is available: Bone marrow is preferred graft source 3

5. For vSAA in younger patients, don't default to IST: Consider upfront haploidentical HSCT given superior failure-free survival 5

Quality of Life Considerations

HSCT provides superior health-related quality of life compared to IST + eltrombopag (p<0.0001) 5, which is an important consideration when counseling patients about treatment options, particularly when survival outcomes are similar.